News Sentiment

IMMP sentiment intelligence

Immutep Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.41 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.2% over one week, +9.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Immutep(IMMP) Stock Options Chain | Quotes & News

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -2.2% Price reacting lower
Trend fit Trend inactive 9.5% over four weeks
Fair value -78.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 33
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 7
Stock Titan 6
GlobeNewswire 6
DirectorsTalk Interviews 5
Moomoo 3
PR Newswire 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 16
Regulatory and legal 6
Analyst action 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Moomoo Direct company coverage

Immutep(IMMP) Stock Options Chain | Quotes & News

This entry consists solely of a title and indicates a stock options chain, quotes, and news for Immutep (IMMP). No further article content was provided.

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 09:11
Source
Moomoo
Sharecafe Direct company coverage

Immutep highlights encouraging survival data and key clinical milestones

Immutep (ASX: IMM; Nasdaq: IMMP) CEO Marc Voigt discussed encouraging new overall survival data from the INSIGHT-003 trial, showing patients achieved a median overall survival of over 30 months. He also provided updates on the ongoing root cause analysis for the TACTI-004 Phase I

Tone
Positive 86/100
Event
Market update
Published
16 Jul 2026 01:41
Source
Sharecafe
Moomoo Direct company coverage

Immutep Granted New US Patent for Cancer Treatment Methods

Immutep, a biotechnology company, has been granted a new U.S. patent for its intellectual property covering methods of treating cancer using its IMP321 (eftilagimod alpha) product. The patent, which extends protection until January 2038, specifically covers the use of IMP321 in c

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 18:13
Source
Moomoo
Stock Titan Direct company coverage

A new Immutep patent covers cancer treatment with eftilagimod alfa through 2036

Immutep (NASDAQ: IMMP) has secured its fourth U.S. patent for eftilagimod alfa (efti) in combination with PD-1 pathway inhibitors, which protects methods for treating cancer and is valid until January 20, 2036. This new patent strengthens Immutep's intellectual property estate fo

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 18:13
Source
Stock Titan
GuruFocus Direct company coverage

Immutep (IMMP) Secures New Patent for Cancer Treatment Innovatio

Immutep (IMMP) has secured a new patent for its cancer treatment innovation. This development is expected to strengthen the company's intellectual property in the biotechnology sector. Further details about the specific innovation and its implications for cancer treatment are ant

Tone
Positive 70/100
Event
Market update
Published
14 Jul 2026 14:18
Source
GuruFocus
Market source Direct company coverage

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Immutep Limited has announced the grant of its fourth United States patent for eftilagimod alfa in combination with PD-1 pathway inhibitors for cancer treatment. This patent, expiring in 2036, expands the company's intellectual property and supports future development and busines

Tone
Positive 70/100
Event
Market update
Published
14 Jul 2026 11:39
Source
Market source
Stock Titan Direct company coverage

[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC Filing - Form 6-K

Immutep Limited reported mature results from its INSIGHT-003 Phase I trial, showing a median Overall Survival of 30.9 months for eftilagimod alfa (efti) in first-line advanced non-squamous NSCLC, which compares favorably to historical benchmarks despite a high proportion of patie

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 09:39
Source
Stock Titan
grafa.com Direct company coverage

Immutep secures USPTO patent for cancer treatment anew

Immutep (ASX:IMM) has secured a fourth patent from the United States Patent and Trademark Office for its combination cancer immunotherapy treatments, protecting future clinical development and business opportunities. The patent is set to expire in 2036. Following the announcement

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 06:00
Source
grafa.com
BiotechDispatch Direct company coverage

Immutep cancer candidate shows strong median survival in lung cancer as company considers conflicting trial results

Immutep (ASX:IMU) has released mature overall survival data from its INSIGHT‑003 trial for eftilagimod alfa (efti) in first-line non‑squamous non‑small cell lung cancer, showing a median overall survival of 30.9 months. These positive results, particularly in patients with low PD

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 00:12
Source
BiotechDispatch
Moomoo Direct company coverage

Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial

Immutep announced that its efti plus pembrolizumab combination therapy showed a median overall survival of 30.9 months in a Phase I trial for previously treated non-small cell lung cancer patients. This data, presented at the ESMO Immuno-Oncology Asia Congress 2023, is mature and

Tone
Positive 94/100
Event
Market update
Published
13 Jul 2026 08:12
Source
Moomoo
Stockhead Direct company coverage

Health Check: Immutep shares bounce on revived lung cancer treatment hopes

Immutep (ASX:IMM) shares surged 30% after releasing positive overall survival data from its INSIGHT-003 lung cancer study, offering renewed hope for its eftilagimod alfa treatment. This comes after the previous TACTI-004 trial was discontinued due to a futility analysis. The comp

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 02:41
Source
Stockhead
Kalkine Direct company coverage

Immutep (ASX:IMM) Reports Mature Survival Data From INSIGHT-003 Trial

Immutep (ASX:IMM) has released mature overall survival data from its INSIGHT-003 trial for first-line non-small cell lung cancer, showing a median overall survival of 30.9 months, which compares favorably to a 22.0-month median overall survival in a similar registrational trial.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 01:41
Source
Kalkine
Barchart Direct company coverage

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is reminding investors of a class action lawsuit against Immutep Limited (NASDAQ: IMMP) for alleged securities fraud. The lawsuit claims Immutep made false and misleading statements about its TACTI-004 trial, which the company allegedly knew would fail its pri

Tone
Negative 28/100
Event
Regulatory and legal
Published
07 Jul 2026 17:10
Source
Barchart
Intellectia AI Direct company coverage

IMMP Financials: Revenue Breakdown, Margins & Competitor Comparison

Immutep Ltd (IMMP) generates its revenue primarily from Cancer Immunotherapy, which accounts for 51.4% of its sales. The company exhibits a strong gross margin of 100.00% but shows negative operating and net margins, indicating challenges in translating revenue into profit. IMMP,

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 10:41
Source
Intellectia AI
GlobeNewswire Direct company coverage

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR). The lawsuits allege materially false and/or misleading statements regarding inventory m

Tone
Negative 18/100
Event
Regulatory and legal
Published
01 Jul 2026 10:40
Source
GlobeNewswire
TradingView Direct company coverage

Price to book forward of Immutep Ltd – LS:A2H81H

The article provides financial information for Immutep Ltd (A2H81H) on Lang & Schwarz Tradecenter via TradingView. It specifically focuses on the "Price to book forward" metric. The page offers an overview of financials, news, and technical analysis, set within the broader Tradin

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 07:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Immutep Ltd – MUN:YP1B

The article displays the enterprise value to EBITDA forward for Immutep Ltd (MUN:YP1B) on the Munich Stock Exchange. It indicates that the market is closed with no trades. The core content is a financial metric displayed within the TradingView platform.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 06:40
Source
TradingView
GlobeNewswire Direct company coverage

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6,

Bernstein Liebhard LLP reminds investors of Immutep Limited (NASDAQ: IMMP) who suffered losses that they have until July 6, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Immutep made false and misleading statements, leading to artificially inflat

Tone
Negative 28/100
Event
Regulatory and legal
Published
29 Jun 2026 18:10
Source
GlobeNewswire
TradingView Direct company coverage

YP1A Forecast — Price Target — Prediction for 2027

The article provides a price target and analyst ratings for Immutep Ltd Sponsored ADR (YP1A) for 2027. One analyst offers a 1-year price forecast of 1.32. Based on two analysts, no specific estimates for EPS or revenue are detailed in the provided content.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 13:14
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Immutep Ltd – ASX:IMM

This page provides financial data for Immutep Ltd (ASX:IMM), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market was closed with no trades at the time of viewing, suggesting the data presented is for informational purposes.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

A2H8YL Forecast — Price Target — Prediction for 2027

This article provides a price target and analyst ratings for Immutep Ltd Sponsored ADR (A2H8YL). One analyst offers a 1-year price forecast, with a target of 1.32. The ratings are based on two analysts over the past three months.

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 13:10
Source
TradingView
TradingView Direct company coverage

Immutep Ltd Actuals & Estimates (ASX:IMM)

This article provides an overview of Immutep Ltd (ASX: IMM) stock performance, analyst estimates, and financial data. It covers current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, noting that analysts have a maximum an

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:39
Source
TradingView
TradingView Direct company coverage

Immutep Ltd Actuals & Estimates (FWB:YP1B)

This article provides financial actuals and estimates for Immutep Ltd (FWB: YP1B), an Australian biotechnology company. It details analyst forecasts, historical stock prices, recent earnings and revenue, and confirms that the company does not pay dividends. The report also highli

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Immutep Ltd – FWB:YP1B

This page displays the "Price to sales forward" metric for Immutep Ltd (FWB:YP1B) on the Frankfurt Stock Exchange. The specific value, change, and percentage change for this metric are presented, though the actual numerical data is not visible in the provided content. The page al

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Immutep Ltd – FWB:YP1B

The article discusses the enterprise value to EBITDA forward for Immutep Ltd (FWB:YP1B) on the Frankfurt Stock Exchange. It provides financial context for the company's valuation metrics.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 05:10
Source
TradingView